HOME >> BIOLOGY >> NEWS
Flying in tune: Buzz brings mosquito pairs together

Human beings are not the only animals keenly attuned to the high-pitched buzzing of mosquitoes--in fact, researchers have discovered, mosquitoes of both sexes are themselves highly responsive to the sounds of other mosquitoes and enter into complex mid-flight pre-mating duets that serve as a means of sex recognition.

The findings are reported in the July 12th issue of Current Biology by Gabriella Gibson of the Natural Resources Institute at the University of Greenwich and Ian Russell of the University of Sussex.

It has been known for decades that the highly specialized hearing organ of male mosquitoes enables them to detect and locate females. In the meantime, the potential for female responsiveness to sound has been overlooked, mainly because their antennae are so much simpler in form. Nonetheless, their auditory sensitivity is among the best of all insects analyzed thus far. Gibson and Russell have now demonstrated that pairs of flying Toxorhynchites brevipalpis respond to each other in a feedback-like interaction, such that each alters its own flight tone in response to the flight tone of the other. This interaction continues until the tones converge, in the case of male-female pairs, or dramatically diverge, in the case of same-sex pairs.

This flight-tone communication effectively serves as a mechanism for bringing together mosquitoes only of opposite sexes during pre-mating encounters and may hold the key to understanding how closely related species recognise con-specifics--that is, members of their own kind--because, the authors suggest, it is unlikely that identical sex-specific flight tones will be shared among different mosquito species.


'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
10-Jul-2006


Page: 1

Related biology news :

1. Flying tip of bees: Leave your legs dangling!
2. MIT study: Maturity brings richer memories
3. Variant CJD -- Prion amplification breakthrough brings new insights and hopes for a blood test
4. Extracting eggs from pre-pubertal cancer patients brings hope for future fertility
5. Dilbert of academia brings humor to talk at UH
6. Disorderly protein brings order to cell division
7. $1 million Myers Fellowship brings US research techniques to Melbourne
8. SNMs 53rd Annual Meeting: Research brings new world of diagnosing, treating illness
9. Research milestone brings goal closer of cheap antimalarial drug for developing world
10. Acupuncture versus acid reflux: 40% cut in sphincter relaxations brings hope for relief
11. Innovative collaboration brings Arctic science into the classroom

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Flying tune Buzz brings mosquito pairs together

(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
(Date:5/20/2013)... Science Foundation (NSF) planning grant will help establish the ... program of the University of Illinois at Urbana-Champaign and ... will be devoted to research in drying moist, porous ... and paper products; chemical products; textiles; and biopharmaceuticals," said ... science and human nutrition and the Illinois site director. ...
(Date:5/19/2013)... strain of electricity-producing bacteria that can grow using hydrogen ... as its sole source of carbon. Researchers at ... the 113th General Meeting of the American Society for ... production solely on hydrogen," says Amit Kumar, a researcher ... part of the Lovley Lab Group at the university. ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... , May 21, 2013 According ... Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market ... - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," ... 2011 and is expected to grow at a CAGR ... estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: